- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that Lonnie Moulder, President and Chief Executive Officer, will present a company overview at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 at 2:40 p.m. EDT, at The New York Palace Hotel in New York City.
A live webcast of the presentation will be available in the Investor Relations section of the company's website at www.abraxisbio.com as well as www.veracast.com/webcasts/bas/healthcare09/id72210376.cfm. The webcast will be archived and accessible at both locations for at least 14 days.
About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.
For more information, please click here
Investor & Media Inquiries
Director Investor Relations & Corporate Communications
Copyright © Business Wire 2009If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016